Epilepsy News and Research

Latest Epilepsy News and Research

Parents administering highly complex medication regimens require additional supports

Parents of children with chronic conditions make many mistakes when giving lifesaving medicines, according to a study being presented Monday, May 3 at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

At the 2010 American Association of Neurological Surgeons Annual Meeting, May 1-5 at the Pennsylvania Convention Center, Elekta will host a series of presentations highlighting Elekta Neuromag, a tool that measures and records brain activity using magnetoencephalography technology.

From Elekta 30 Apr 2010

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax, the Justice Department announced today.

30 Apr 2010

Natus Medical's revenue for first-quarter 2010 increased 47% to $49.2M

Natus Medical Incorporated today announced financial results for the three months ended March 31, 2010.

29 Apr 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

28 Apr 2010

Natus Medical announces $50M revolving credit facility with Wells Fargo Bank

Natus Medical Incorporated today announced that it has entered into a $50 million revolving credit facility with Wells Fargo Bank, National Association. The credit facility, which matures on April 30, 2012, amends and restates the Company's existing $25 million credit facility that was scheduled to mature on April 30, 2010.

27 Apr 2010

Tel Aviv University researcher maps drug target to wipe pain away

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate chronic pain, and as much money is spent by the healthcare system to diagnose what's wrong.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

Catalyst Pharmaceutical Partners, Inc. announced today that it has received notice from The NASDAQ Stock Market confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

27 Apr 2010

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Pro-Tect Pharmaceuticals, Inc. announced that it has completed the acquisition of multiple patents and patents-pending from Nectid, Inc., that enable three revolutionary drug delivery technologies.

26 Apr 2010

Study finds changes in astrocytes key to brain dysfunction

Neuroscience researchers have zeroed in on a novel mechanism that helps control the firing of electrical signals among neurons. By isolating the molecular and electrical events that occur when this control is disrupted, the new research sheds light on epileptic seizures and potentially on other prominent diseases involving poorly regulated brain activity.

26 Apr 2010

New understanding of nerve cell influence in exchange of information

Nerve cells communicate with each other by means of electrical impulses. To create such an impulse, the cells exchange charged ions with their environment. However, the role played by the ever-present chloride channels remained obscure, although some theories predicted a relation between the chloride channel ClC-2 and epilepsy.

24 Apr 2010

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.

23 Apr 2010

NREF announces fellowship funding for 2010-2011

The Neurosurgery Research and Education Foundation (NREF), which reached an agreement with Codman & Shurtleff, Inc. (Codman) in December 2009 to provide funding to the NREF in support of the Foundation's new post-residency, clinical fellowship grant program, is pleased to announce that the following programs have been awarded fellowship funding for 2010-2011: Baylor College of Medicine (pediatric neurosurgery), Brigham & Women's Hospital (general neurosurgery),

23 Apr 2010

Researchers take major step to predict adverse drug reactions using genetic information

In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.

23 Apr 2010

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Icagen, Inc. today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy.

21 Apr 2010

New self-referencing glutamate biosensor to measure glutamate flux of neural cells in living organism

A new biosensor developed at Purdue University can measure whether neurons are performing correctly when communicating with each other, giving researchers a tool to test the effectiveness of new epilepsy or seizure treatments.

21 Apr 2010

Systems biologists integrate new genetic framework to help predict adverse drug reactions

In a major step toward predicting adverse drug reactions, systems biologists at Mount Sinai School of Medicine in New York City have integrated genetic, cellular and clinical information to find out why certain medicines can trigger fatal heart arrhythmias.

21 Apr 2010

Researchers find no correlation between AED drug load and number of adverse effects in epileptic patients

Researchers have found that polytherapy with multiple anti-epileptic drugs did not result in greater adverse effects than monotherapy for patients with refractory epilepsy. This observational study also found AED load was not a factor in causing adverse effects, but suggests that individual susceptibility, type of AEDs used, and physicians' skills determine which patients suffer adverse effects.

20 Apr 2010

Epileptic activity in brain can affect language development in children: Sahlgrenska Academy

Epileptic activity in the brain can affect language development in children, and EEG registrations should therefore be carried out more frequently on children with severe language impairment to identify more readily those who may need medical treatment, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg.

20 Apr 2010

Epilepsy News and Research

Latest Epilepsy News and Research

Parents administering highly complex medication regimens require additional supports

Elekta Neuromag tool to be highlighted at AANS 2010 Annual Meeting

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

Natus Medical's revenue for first-quarter 2010 increased 47% to $49.2M

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Natus Medical announces $50M revolving credit facility with Wells Fargo Bank

Tel Aviv University researcher maps drug target to wipe pain away

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Study finds changes in astrocytes key to brain dysfunction

New understanding of nerve cell influence in exchange of information

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

NREF announces fellowship funding for 2010-2011

Researchers take major step to predict adverse drug reactions using genetic information

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

New self-referencing glutamate biosensor to measure glutamate flux of neural cells in living organism

Systems biologists integrate new genetic framework to help predict adverse drug reactions

Researchers find no correlation between AED drug load and number of adverse effects in epileptic patients

Epileptic activity in brain can affect language development in children: Sahlgrenska Academy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Epilepsy News and Research

Latest Epilepsy News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in